GSK plc (NYSE:GSK) Shares Bought by Stockman Wealth Management Inc.

Stockman Wealth Management Inc. grew its position in GSK plc (NYSE:GSK) by 2.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 188,925 shares of the pharmaceutical company’s stock after purchasing an additional 4,134 shares during the quarter. GSK makes up 1.4% of Stockman Wealth Management Inc.’s investment portfolio, making the stock its 29th largest position. Stockman Wealth Management Inc.’s holdings in GSK were worth $7,002,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of GSK. Versant Capital Management Inc lifted its holdings in GSK by 2,816.7% during the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 676 shares during the last quarter. Larson Financial Group LLC increased its stake in GSK by 271.8% in the third quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 647 shares during the last quarter. BKM Wealth Management LLC purchased a new stake in shares of GSK during the 4th quarter worth approximately $32,000. Jones Financial Companies Lllp raised its stake in GSK by 62.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after acquiring an additional 509 shares in the last quarter. Finally, Washington Trust Advisors Inc. acquired a new stake in shares of GSK during the third quarter worth about $53,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GSK has been the topic of several research reports. Morgan Stanley began coverage on shares of GSK in a research report on Tuesday, January 23rd. They set an “equal weight” rating on the stock. Jefferies Financial Group upgraded GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Finally, Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy”.

GSK Price Performance

GSK stock traded up $0.85 on Monday, reaching $40.60. 3,800,630 shares of the company’s stock were exchanged, compared to its average volume of 3,486,465. The stock has a fifty day moving average of $41.88 and a 200-day moving average of $38.86. The firm has a market cap of $84.14 billion, a PE ratio of 13.49, a P/E/G ratio of 1.40 and a beta of 0.64. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 1.19. GSK plc has a twelve month low of $33.33 and a twelve month high of $43.84.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). The company had revenue of $10 billion for the quarter, compared to analysts’ expectations of $9.79 billion. GSK had a return on equity of 51.45% and a net margin of 16.24%. As a group, equities analysts predict that GSK plc will post 4.03 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, April 11th. Investors of record on Friday, February 23rd were given a dividend of $0.3564 per share. This is an increase from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 annualized dividend and a dividend yield of 3.51%. The ex-dividend date was Thursday, February 22nd. GSK’s payout ratio is currently 52.82%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.